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Purpose: Limited information is available comparing toxicity of accelerated radiotherapy
(RT) to that of standard fractionation RT for early stage breast cancer. We report early and
late toxicities of two prone regimens of accelerated intensity-modulated radiation therapy
(IMRT) with a concomitant boost (CB) to the tumor bed delivered over 3 or 5weeks as
compared to standard 6week RT with a sequential electron boost. Methods: From 2/2003
to 12/2007 , 169 consecutive patients with Stage I–II breast cancer were offered the choice
to undergo prone RT with either: a 6-week standard RT regimen of 46Gy/23 fractions (fx) to
the whole breast (WB), followed by a14 Gy sequential boost (SB) to the tumor bed (6wSB),
a 5-week regimen of 50Gy toWB with an IMRT CB of 6.25Gy in 25 fx (5wCB); or a 3-week
protocol of 40.5Gy toWB with an IMRT CB of 7 .5Gy in 15 fx (3wCB).These regimens were
estimated as biologically equivalent, based on alpha/beta=4 for tumor control. Toxicities
were reported using RTOG and LENT/SOMA scoring. Results:51/169 patients chose stan-
dard 6wSB, 28 selected 5wCB, and 90 enrolled in 3wCB protocol. Maximum acute toxicity
was Grade 3 dermatitis in 4% of the patients in the 6wSB compared 1% in 3wCB. In gen-
eral, acute complications (breast pain, fatigue, and dermatitis) were signiﬁcantly less in the
3wCB than in the other schedules (P <0.05). With a median follow-up of 61months, the
only Grade 3 late toxicity was telangiectasia in two patients: one in 3wCB and one in 5wCB
group. Notably, ﬁbrosis was comparable among the three groups (P =NS). Conclusion:
These preliminary data suggest that accelerated regimens of breast RT over 3 or 5weeks
in the prone position, with an IMRT tumor bed CB, result in comparable late toxicity to
standard fractionation with a sequential tumor boost delivered over 6weeks. As predicted
by radiobiological modeling the shorter regimen was associated with less acute effects.
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INTRODUCTION
Management of early breast cancer involves a multimodality
approach employing surgery, radiotherapy (RT), chemother-
apy, and hormonal therapy, requiring considerable health care
resources.Forwomenundergoingbreast-conservingsurgery,stan-
dard fractionation radiotherapy results in excellent cosmesis in
most cases (Shaﬁq et al., 2007), and a recent meta-analysis from
17randomizedtrialsdemonstratesthatitproducesa15.7%reduc-
tioninthe10-yearsriskofanyﬁrstrecurrenceandresultsina3.8%
absolute reduction of breast cancer death at 15years (Darby et al.,
2011).
To enhance adherence and reduce costs, strategies have been
developed to reduce the overall treatment time and number of
visits to the radiation facilities,using accelerated treatment sched-
ules which increase the dose per fraction and/or a concomitant
boost (CB) to the tumor bed (Formenti et al., 2007; van der Laan
et al.,2007; Jalali et al., 2008).
The general rationale for including a boost to the tumor bed
is based on 10years results of the European Organization for
Research and Treatment of Cancer (EORTC) “boost/no boost”
trial that demonstrated a reduction in local recurrence rate when
a16-Gyboostwasincluded(6.2vs.10.2%,P <0.0001;Poortmans
etal.,2008).CBviaIMRTimprovesdoseconformalitytothebreast
and boost regions while allowing for the delivery of a larger dose
per fraction to the area at high risk of residual microscopic can-
cer. The concomitant technique shortens the radiotherapy course
by 1–3weeks while maintaining the biological beneﬁt of a dose
increment at the tumor bed site.
Little comparative data with regards to toxicity amongst differ-
entfractionationapproachesisavailableforthetreatmentofbreast
cancer, particularly in the prone position. To our knowledge, no
prospective randomized studies have compared daily radiother-
apy over 3 or 5weeks with a CB to the tumor bed to the standard
6weeks regimen that includes a consecutive boost.
We identiﬁed in our database a consecutive group of patients
who had undergone breast-conservation surgery and who, at ini-
tial consultation for post-operative radiotherapy, were offered,
based on their tumor characteristics, to choose among three
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approaches: standard 6week radiation therapy with a sequential
boost(6wSB),aregimenof5weeksofdailyradiotherapywithaCB
using IMRT (5wCB) or a protocol of 3weeks daily radiotherapy
with a CB using IMRT (3wCB),respectively. Each patient was ﬁrst
offered standard therapy and then informed about the two accel-
erated regimens. Patient’s preference dictated the choice of treat-
ment,asdocumentedinthemedicalrecord.Wecompareacuteand
late toxicity outcomes for patients treated on the three regimens.
MATERIALS AND METHODS
STUDY DESIGN AND ELIGIBILITY
The study was approved by the NYU Institutional Review Board
and the collection, storage, and retrieval of data were all done
in compliance with the Health Insurance Privacy and Portabil-
ity Act. The consecutive cohort was deﬁned as Stage I–II breast
cancer patients who, after segmental mastectomy with negative
margins, were offered the choice to undergo whole breast radio-
therapy either with a standard fractionation regimen of 6weeks
that included a sequential boost (SB) to the tumor bed or with a
hypo-fractionation regimen of 3 or 5weeks with IMRT to deliver
a CB to the tumor bed. Patients were identiﬁed from the depart-
mentalrecordandverifydatabases(ARIA,VarianMedicalSystem,
Palo,Alto, CA, USA).
A total of 169 consecutive patients with the above characteris-
tics were identiﬁed. In 159/169 patients a documented follow up
visit,atleastayearaftercompletingradiotherapywasavailablefor
evaluation of late effects.
RADIOBIOLOGIC RATIONALE FOR DOSE AND FRACTIONATION
SCHEDULE
The 6-week schedule (6wSB) prescribed 60Gy in 30 fractions of
2Gy over 6weeks: the ﬁrst 23 fractions targeting the whole breast
prone, followed by the remaining 7 fractions targeting the tumor
bed with an electron boost ﬁeld,set-up in supine position. The 5-
week CB schedule (5wCB) delivered 50Gy in 25 fractions of 2Gy
to the prone breast, with a daily CB of 25 cGy to the tumor bed,
over a total of 5weeks. Finally, the 3week CB schedule (3wCB)
delivered a total dose of 40.5Gy, at 2.7Gy in 15 fractions to the
pronebreastwithanadditionalCBof0.5Gydeliveredtothetumor
bed, for a total dose of 48Gy to the lumpectomy site. The results
of the latter regimen were previously reported (DeWyngaert et al.,
2007; Formenti et al.,2007).
The linear-quadratic model (Fowler, 1989) was used to deter-
mine whether the proposed accelerated intensity-modulated RT
(AIMRT) protocol yields a roughly equal probability of tumor
control compared with a standard schedule, using a tumor α/β
of 4. This is the same α/β value that Owen et al. (2006) derived
basedonUKNationalCancerResearchInstitute(NCRI)random-
ized trial which evaluated three dose schedules for breast cancer
treatment.BEDsforthestandardandacceleratedIMRTschedules
werecalculated,aspreviouslydescribed(DeWyngaertetal.,2007),
assuming that full repair takes place during the ≥24-h interval
between fractions.
Table 1 lists the BEDs for tumor control, early responses to
radiationeffects(erythemaanddesquamation),andlateresponses
(telangiectasia and ﬁbrosis) for the three fractionation schedules.
The choices for the α/β values used for these computations have
Table 1 | Biologically equivalent doses for late effects and tumor
control.
α/β (Gy) 6WSB
Schedule*
5wCB
Schedule
†
3wCB
Schedule
††
2Gy×23
in 39days
2Gy×25
in 32days
2.7Gy×15
in 18days
LATE EFFECTS
Fibrosis 2 92 Gy2 100 Gy2 95 Gy2
Telangiectasia 4 69 Gy4 75 Gy4 68 Gy4
Erythema 8 58 Gy8 63 Gy8 54 Gy8
Desquamation 11 54 Gy11 59 Gy11 50 Gy11
α/β (Gy) 6WSB
Schedule
5wCB
Schedule
3wCB
Schedule
2Gy×23
in 39days
2Gy×25
in 32days
3.2Gy×15
in 18days
TUMOR CONTROL
Tumor 2 120 Gy2 120 Gy2 125 Gy2
Tumor§ 2 116 Gy2 118 Gy2 125 Gy2
Tumor 4 90 Gy4 88 Gy4 86 Gy4
Tumor§ 4 86 Gy4 86 Gy4 86 Gy4
Tumor 10 72 Gy10 69 Gy10 63 Gy10
Tumor§ 10 68 Gy10 67 Gy10 63 Gy10
*6wSB, 6-Week sequential boost;
†5wCB, 5-week concomitant boost;
††3wCB,
3-week concomitant boost; §, taking into account cell proliferation during the
course of treatment.
been justiﬁed in previous studies (Steel et al., 1987; Matthews
et al., 1989; Turesson and Thames, 1989; Thames et al., 1990;
Archambeau et al.,1995;Yamada et al.,1999).
Bothhypo-fractionatedschedulesarealsoacceleratedprotocols
inwhichthetotaldoseisdeliveredin32or18daysvs.thestandard
schedule delivered over 39days. Accounting for tumor prolifera-
tion that will take place during the additional treatment (Travis
and Tucker,1987; Fowler,1989; Stanton et al.,1996; Haustermans
etal.,1998)aspresentedinTable 1,theinclusionofacellprolifera-
tioncorrectionfactorproducessmalldecreasesintheBEDsforthe
standard treatment. Therefore, taking into consideration tumor
proliferation during treatment, an alpha/beta of 4 corresponds to
equivalent tumor control probability among the three schedules.
TheBEDcalculationsforthe5wCBscheduleestimateaslightly
higher rate of early effects, erythema and desquamation and of
late telangiectasia and ﬁbrosis as compared with the standard
fractionation schedule. Conversely, the BED calculations of the
3wCB schedule estimate a lower rate of acute effects of erythema,
desquamation, and comparable late effects to those of standard
fractionation.
PRONE PATIENT SET-UP AND COMPUTED TOMOGRAPHY SIMULATION
All patients were placed in the prone position on a dedicated
treatmentplatformforcomputedtomography(CT)planningand
treatment. The platform, placed on top of the CT couch, con-
tains an open aperture on one side to allow for the index breast
to fall away from the chest wall. Before the patients lay down
prone on the platform for CT scanning, they were positioned
supine and a radiation oncologist placed ﬁducial markers on their
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skin to clinically deﬁne the medial, lateral, caudal, and cepha-
lad breast ﬁeld borders. Subsequently, non-contrast CT images
were acquired at 2.5–3.75mm-thick intervals, from the level of
the mandible to below the diaphragm. Details on the NYU prone
technique were previously reported (Huppert et al., 2011).
TREATMENT PLANNING FOR THE STANDARD 6-WEEK RT SCHEDULE
The standard schedule consisted of a 2-Gy daily fraction delivered
5days a week to a dose of 46Gy to the whole breast, followed by
a SB to the lumpectomy cavity treated either supine with en-face
electrons or, less frequently, prone using photon tangents ﬁelds
prone. Field deﬁnition to treat the entire breast was based on the
following: opposed tangent photon beams were used to treat the
entire breast tissue as identiﬁed at CT, in the prone position from
midline and with the posterior edge of the ﬁeld extending to the
anterior edge of the latissimus dorsi muscle laterally.
The prone whole breast plans were created with two, three, or
four ﬁelds using a ﬁeld in-ﬁeld technique and enhanced dynamic
wedges as necessary using 3D-CRT planning. The boost target
volume was contoured using evidence of the persisting surgi-
cal cavity at CT simulation and/or based on review of original
patient records including mammography, ultrasound, magnetic
resonance imaging, and operative records.
TREATMENT PLANNING FOR CONCOMITANT BOOST SCHEDULES
(5wCB AND 3wCB DEFINITION OF PLANNING TARGET VOLUMES)
Patientsinthe5-and3-weekCBregimenweretreatedintheprone
positionusing6MVphotonsusingthetechniqueofCBIMRTpre-
viouslydescribed(DeWyngaertetal.,2007).Patientsinthe5-week
scheduleweretreatedwith50Gyin25dailyfractionsof2Gytothe
whole breast (PTV1) prescribed to the 100% isodose line with the
tumor bed region (PTV2) boosted daily by an additional 0.25Gy,
using IMRT (total boost dose 6.25Gy). For patients in the 3wCB
protocol the whole breast (PTV1) was treated to a daily fraction
dose of 2.7Gy, with the tumor bed region (PTV2) boosted by an
additional 0.5Gy,using IMRT (total boost dose 7.5Gy).
Separate non-coplanar IMRT ﬁelds were speciﬁcally designed
to deliver the boost dose to the lumpectomy site on top of the
ipsilateral whole breast dose planned using conventional 3D con-
formal techniques (Formenti et al., 2007). In the majority of
patients, a two ﬁeld IMRT ﬁeld approach similar to mini-tangent
non-coplanarbeamarrangementwasusedtotargetthetumorbed.
Thewholebreastplanswerecreatedusingtwoorthreeﬁelds,with
enhanced dynamic wedges as necessary. These plans were used as
a base plan for optimization of the boost ﬁelds. The optimization
andcalculationsweredoneusingEclipsesoftware(VarianMedical
Systems,PaloAlto,CA,USA)usinggradient-dependentoptimiza-
tion algorithm to satisfy dose-volume objectives and constraints
forPTV1,PTV2,body,lung,andheart.Thegoalsof planningwere
to deliver a CB to the tumor bed and to minimize the size of the
hot spot volumes outside of PTV2. Planning constraints limited
5% of the heart volume to receive 18Gy and 10% of the ipsilateral
lung volume to receive less than 20Gy.
ASSESSMENT OF TOXICITIES
Acute skin toxicity was assessed by the treating radiation oncolo-
gist as a part of the standard weekly assessment, during radiation
treatment, with the maximum toxicity scored during and within
90days of radiation. Individual indices for acute skin toxicity like
faint erythema, bright or brisk erythema, dry desquamation, and
wet desquamation were noted. Late toxicity was assessed at least a
year after radiotherapy and then yearly thereafter. For late skin
toxicities, asymmetry, edema, telangiectasia, induration, hyper-
pigmentation, and ﬁbrosis were recorded. The reported toxicities
scorerepresentsthemaximalpointof toxicityassignedduringand
aftertheradiationtreatmentorreportedbythepatientduringand
after RT completion.
Toxicities were scored according to the Radiation Therapy
Oncology Group (RTOG)/the EORTC toxicity scale associated
with radiation, and the late effects of normal tissue-subjective
objective management analytical (LENT/SOMA) scale (Hoeller
et al.,2003) for delayed toxicities as shown in Table 2.
STATISTICAL METHODS
Patient and disease characteristics were compared using pair-wise
comparisons among the 3wCB, 5wCB, and 6wSB schedules using
the Fischer’s exact test using the SAS statistical software program.
Pair-wise comparisons using Fischer’s exact test were also per-
formed to compare the three schedules with regard to acute and
late toxicities.
RESULTS
FromFebruary2003toJanuary2005,51patientsselectedthestan-
dard 6wSB, 28 patients the 5wCB and 90 patients the 3wCB regi-
men. Patient characteristics are described in Table 3 that includes
the results of pair-wise comparisons between the schedules, cal-
culated by the Fisher’s exact test using the SAS statistical software
program.
The patient and treatment characteristics were similar among
the three groups regarding age (median 52, 54, and 57 for the
standard, 5wCB and 3wCB groups, respectively), KPS, tumor and
nodal staging, and histology. There were more white and fewer
Hispanic patients treated with the 3wCB than the 5wCB sched-
ule,P =0.021andP =0.018,respectively.Thereweresigniﬁcantly
less patients with estrogen receptor positive status in the 5wCB
group than in the other groups (P <0.05),and signiﬁcantly more
HER2/NEUnegativepatientsinthe3wCBcohortthanintheother
two groups (P <0.05). More patients in the 3wCB group received
anti-hormonetherapyascomparedwithboththe5wCBand6wSB
schedules (P <0.05). Finally, about the same ratio of patients in
all three groups received chemotherapy (P =NS), in most cases
consisting of a combination of doxorubicin, cyclophosphamide,
and paclitaxel.
ACUTE TOXICITY
Noneof thepatientsunderwenttreatmentbreaksbecauseof acute
toxicity. Table 4 describes the incidence of acute toxicity dur-
ing radiation therapy, consisting mainly of radiation dermatitis.
Speciﬁcally, Grade 1 radiation dermatitis was observed in 27% of
therecipientsof6wSB,27%of5wCB,and58.5%of3wCB.Grade2
dermatitiswasseenin68.6%of patientson6wSB,73%of patients
on 5wCB, and 8.1% of patients on 3wCB regimen. Grade 3 skin
reactions were noted in 2 patients (4%) from 6wSB vs. one (0.9%)
in the 3wCB regimen and in none of those treated with the 5wCB
regimen.Figure1demonstratesapatientwhowastreatedwiththe
6-week standard fractionation regiment exhibiting Grade 2 brisk
erythema at the end of treatment.
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Table 2 | Scoring for acute and late toxicities.
A.Acute radiation dermatitis
Common terminology criteria for radiation dermatitis
1 Faint erythema or dry desquamation
2 Moderate to brisk erythema; patchy moist desquamation, mostly conﬁned to skin folds and creases; moderate edema
3 Moist desquamation other than skin folds and creases; bleeding induced by minor trauma or abrasion
4 Skin necrosis or ulceration of full thickness dermis; spontaneous bleeding from involved site
5 Death
B. Late toxicity scoring according to the RTOG/EORTC and LENT/SOMA*
Grade 1 Grade 2 Grade 3 Grade 4
RTOG/EORTC
Skin Slight atrophy, pigmentation
change, some hair loss
Patchy atrophy, moderate
telangiectasia, total hair loss
Marked atrophy, gross
telangiectasia
Ulceration
Subcutaneous tissue Slight induration (ﬁbrosis),
and loss of subcutaneous fat
Moderate ﬁbrosis, but
asymptomatic; slight ﬁeld
contracture, ≤10% linear reduction
Severe induration and loss of
subcutaneous tissue, ﬁeld
contracture, ≥10% linear reduction
Necrosis
LENT/SOMA – BREAST SUBJECTIVE
Pain Occasional and minimal
hypersensation, pruritus
Intermittent and tolerable Persistent and intense Refractory,
excruciating
LENT/SOMA – BREAST OBJECTIVE
Telangiectasia <1cm 2 1–4 cm2 >4cm 2
Fibrosis Barely palpable, increased
density
Deﬁnite increased intensity and
ﬁrmness
Very marked density, retraction, and
ﬁxation
Edema Asymptomatic Symptomatic Secondary dysfunction
Retraction, atrophy 10–25% >25–40% >40–75% Whole breast
LENT/SOMA – SKIN
Pigmentation change Transitory, slight Permanent, marked – –
RTOG, RadiationTherapy Oncology Group; EORT, European Organization for Research andTreatment of Cancer; LENT/SOMA, late effects of normal tissue task force;
SOMA, subjective, objective, management and analytic.
*Hoeller et al. (2003).
Pair-wise comparisons of acute complications with P-values
less than 0.05 were chosen to detect when the data differed sig-
niﬁcantly in the 5wCB vs. 6wSB, 5wCB vs. 3wCB, and 6wSB vs.
3wCB schedules (Fisher’s exact test, SAS statistical software pro-
gram). All acute complications including breast pain,fatigue,and
dermatitis were signiﬁcantly less frequent among the patients in
the 3wCB than in either the 5wCB or 6wSB schedule (P <0.05).
Breast edema occurred less frequently among patients treated
with the 3-week compared to the 5wCB schedule (P =0.004),
but not signiﬁcantly less compared to the 6-week schedule
(P =0.081).
Figure 2 describes the maximum incidence of acute skin tox-
icity among the three treatment groups: the 6wSB was associ-
ated with increased incidence of acute skin toxicity as compared
with either the 3wCB or 5wCB schedules. The latter two had
comparable patterns.
All patients in the 6wSB and 5wCB schedule and most in the
3wCB developed Grade 1 dermatitis. As shown in Figure 3,a t
week 3 about 70% of patients on the 6wSB and 5wCB schedule
developed Grade 2 dermatitis, while only 11% of patients on the
3wCB protocol. Also, Grade 3 dermatitis at the end of treatment
occurred in 4% of patients on the 6wSB and 1% of patients on the
3wCB at the end of treatment.
Painandfatiguewerealsomoreoftenexperiencedamongrecip-
ientsof the6wSBregimen,withthreepatientsexperiencingGrade
3 pain. Twenty-ﬁve patients (49%) reported pain during 6wSB
regimen compared to only eight patients (28.5%) in 5wCB and
1 (0.9%) in 3wCB group (P <0.05). Fatigue was also more pro-
nounced among recipients of 6wSB: 15.7% compared to 10.7%
in the 5wCB and 0.9% in 3wCB group (P <0.05 for 3wCB as
compared to 5wCB and 6wSB). Patients in the 5wCB schedule
exhibited more edema (43%) compared to 6wSB (29.4%) and
3wCB schedule (15.5%), with statistically signiﬁcant increased
edema seen for patients treated with 5wCB as compared with
3wCB (P <0.05).
LATE TOXICITIES
Late toxicities are listed in Table 5 with a median follow up of
61months. A statistically signiﬁcant difference in late grade ≥1
asymmetry was noted comparing the 3wCB and 5wCB schedule
with conventional 6wSB, with reduced asymmetry noted in both
accelerated schedules (P <0.05).
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Table 3 | Distribution of baseline patient and tumor characteristics among the three groups of patients.
Demographics Standard 6wSB*
(N =51)
AIMRT 5wCB
†
(N =28)
AIMRT 3wCB
††
(N =90)
5wCB vs. 6wSB** 3wCB vs. 5wCB** 3wCB vs. 6wSB**
TUMOR STAGE I
T1a 51 28 90 0.507 0.1864 0.5726
T1b 45 23 82 0.76 0.587 1
T1c 35 19 63 0.815 0.829 1
TUMOR STAGE II
T2a 9 6 17 0.767 0.7877 1
NODAL STAGE
Negative 40 26 72 0.122 0.1526 0.8312
Positive 11 2 18
HISTOLOGY
Ductal carcinoma 50 25 79 0.125 1 0.0557
Lobular carcinoma 0 2 7 0.123 1 0.0487
Mucinous carcinoma 1 1 4 1 1 0.6535
RACE
White 38 19 79 0.603 0.0211 0.0612
Black 5 1 6 0.415 1 0.5266
Hispanic 6 5 3 0.507 0.018 0.0715
Asian 2 2 2 0.34 0.0861 0.6202
TUMOR ESTROGEN RECEPTOR STATUS
Negative 10 14 16 0.01 0.0012 0.8233
Positive 41 14 74
TUMOR PROGESTERONE RECEPTOR STATUS
Negative 19 20 37 0.005 0.0086 0.7217
Positive 32 8 53
TUMOR HER2/NEU STATUS
Negative 40 21 85 0.783 0.0071 0.0058
Positive 11 7 5
CHEMOTHERAPY
No 33 19 60 0.81 1 0.8544
Yes 18 9 30
ANTI-HORMONETHERAPY
No 30 18 18 0.81 2.80-05 5.82-06
Yes 21 10 72
*6wSB, 6-week sequential boost;
†5wCB, 5-week concomitant boost;
††3wCB, 3-week concomitant boost; **Pair-wise comparisons were made between the 5wCB,
6wSB, and 3wCB schedules, using the Fischer’s exact test.
Late complications of telangiectasia, skin pigmentation, and
ﬁbrosis at 5years were comparable among the three groups
(P =NS). Grade III telangiectasia occurred in 1 patient treated
by the 3wCB and in 1 patient in the 5wCB protocol.
Finally, 14% of patients treated with 6wSB regimen, 10% with
the 5wCB and 25.8% of patients on 3wCB developed Grade 1
hyper-pigmentationchanges:onlyonepatient(0.6%)inthe6wSB
developed Grade 2 hyper-pigmentation. Grade 1 ﬁbrosis, deﬁned
asabarelypalpableincreaseddensitycomparedtotheotherbreast,
was noted in 7% in the 6wSB, 2.5% in the 5wCB, and 19% in the
3wCB regimen. Grade 2 ﬁbrosis was less common with the 6wSB
(1.2%) and 5wCB (0.6%) compared to 3wCB regimen (5%).
DISCUSSION
Standard radiation dose fractionation for the treatment of early
stagebreastcancerhastwomainshortcomings:theinconvenience
to patients who attend daily treatment for 6–7weeks and the
cost associated with a prolonged usage of the facilities. Among
the strategies that have been employed to reduce the treatment
time, the Canadian trial by Whelan et al. (2002, 2010) has gen-
erated solid evidence in favor of a hypo-fractionated, acceler-
ated, whole breast irradiation for selected women with early
stage breast cancer. However, at a non-planned subset analy-
sis the hypo-fractionated regimen appeared to be less effective
in patients with high-grade tumors, and it was associated at
10years median follow up with a cumulative incidence of local
recurrence of 15.6% compared to 4.7% among similar patients
assigned to the standard fractionation group (P =0.01; Smith
et al.,2009).
Croog et al. reported the results in a consecutive series of
128 patients treated with a prone IMRT approach consisting
of 16 daily fractions of 265cGy to a total dose of 4,240cGy
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Table 4 | Comparison of acute radiation toxicity among the three regimens.
6wSB* N =51 5wCB
†
N =28 3wCB
††
N =90 5wCB vs. 6wSB** 3wCB vs. 5wCB** 3wCB vs. 6wSB**
BREAST PAIN
Grade 1 25 8 1 0.098 3.21–05 1.40–12
Grade 2 18 5 0 0.126 5.62–04 1.14E–09
Grade 3 3 0 0 0.549 N/A 0.0455
FATIGUE
Grade 2 8 3 1 0.738 0.0411 0.0013
Grade 3 0 0 1 N/A 1 1
RADIATION DERMATITIS
Grade 1 51 28 75 N/A 0.0204 0.0011
Grade 2 37 20 10 1 1.96–09 1.15–13
Grade 3 2 0 1 0.537 1 0.2965
BREAST EDEMA
Grade 1 15 12 14 0.321 0.0041 0.0814
*6wSB, 6-week sequential boost;
†5wCB, 5-week concomitant boost;
††3wCB, 3-week concomitant boost. **Pair-wise comparisons were made between the 5wCB,
6wSB, and 3wCB schedules, using the Fischer’s exact test.
FIGURE 1 | Example of a patient treated with the 6wSB regimen demonstrating Grade 2 erythema during the ﬁnal week of treatment, while receiving
the sequential boost to the upper outer quadrant.
followed by a conventionally fractionated boost,over 29days.At a
median follow-up of 18months, one ipsilateral breast recurrence
developed that was salvaged with mastectomy and immediate
reconstruction (Croog et al.,2009).
Since 2003, we developed a series of research protocols test-
ing feasibility and safety of a CB to the tumor bed, delivered by
IMRT. Results from randomized trials have suggested that both
local control of breast cancer and late change in breast appearance
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FIGURE 2 |Acute toxicities: maximum incidence of erythema and desquamation between the three regimens: 6wSB (6-week sequential boost), 5wC
(5-week concomitant boost), and 3wCB (3-week concomitant boost).
FIGURE 3 | Kinetics of Grade 2 and 3 acute toxicities. Grade 2
toxicity (brisk erythema) was noticed at week 3 in 70% of patients in
5wCB and 6wSB schedules and in only 11% of the patients treated
with 3wCB. Grade 3 dermatitis was seen in 1% of patients in the
3wCB and 4% of patients on the 6wSB schedule at 3 and 6weeks,
respectively.
exhibit similar sensitivity to fraction size as modeled by the α/β
ratio in the linear-quadratic formulation (Bentzen et al., 2008).
Based on radiobiological modeling, we selected regimens that
wouldprovidebiologicaleffectivedoseequivalencetothatof stan-
dard 6-conventional fractionation to 60Gy using an α/β value of
4 for tumor control, and taking into consideration the different
repopulationwithashorter,acceleratedregimen(Rosensteinetal.,
2004). Although BED modeling calculations for the 5wCB sched-
ule estimated a slightly higher rate of early effects, erythema and
desquamation and of late telangiectasia and ﬁbrosis as compared
with the standard fractionation schedule,this was not observed in
thisconsecutiveseriesof patients.Incontrast,BEDcalculationsof
the 3wCB schedule estimated a lower rate of acute effects of ery-
thema, desquamation, and a slight increase in ﬁbrosis compared
toconventionalfractionation,asobservedinthepatientsincluded
in this report.
Other centers have also pilot-tested a CB accelerated fraction-
ation regimen. At Fox Chase, 75 patients were treated with a
hypo-fractionated regiment of IMRT in 20 treatments of 2.25Gy
per day for a total of 45Gy over 4weeks (Freedman et al., 2007).
An electron boost was added, bringing dose to 2.8Gy per frac-
tion for a total of 56Gy to the original tumor bed. Acute toxicity
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Table 5 | Comparison of late toxicity among the three regimens, at 5-year median follow-up (N =159 patients).
6wSB* N =46 5wCB
†
N =23 3wCB
††
N =90 5wCB vs. 6wSB** 3wCB vs. 5wCB** 3wCB vs. 6wSB**
ASYMMETRY
Grade 1 41 14 61 0.01 0.622 0.007
Grade 2 8 0 9 0.045 0.2 0.274
PALPABLE MASS
Grade 1 3 0 11 0.546 0.116 0.382
Grade 2 1 0 1 1 1 1
INDURATION
Grade 1 26 12 61 0.8 0.222 0.257
Grade 2 3 0 9 0.546 0.2 0.751
FIBROSIS
Grade 1 14 5 38 0.572 0.093 0.197
Grade 2 2 1 8 1 0.683 0.494
TELANGIECTASIA
Grade 1 6 4 12 0.721 0.738 1
Grade 2 1 1 5 1 1 0.664
Grade 3 0 1 1 0.333 0.367 1
HYPER-PIGMENTATION
Grade 1 24 16 41 0.203 0.06 0.475
Grade 2 1 0 0 1 N/A 0.338
*6wSB, 6-week sequential boost;
†5wCB, 5-week concomitant boost;
††3wCB, 3-week concomitant boost. **Pair-wise comparisons were made between the 5wCB,
6wSB, and 3wCB schedules, using the Fischer’s exact test.
was tolerable with the majority of patients experiencing only
Grade 1 skin toxicity. Late toxicity was not reported nor were the
results compared to those obtained at the same institution when a
standard fractionation regimen was utilized.
We previously reported the results of the 3wCB trial (Formenti
etal.,2007),butnoprospectivecomparisonof themorbidityasso-
ciated with different fractionation regimens utilizing a boost is
available.Whileevidencetothisregardwouldbebestgeneratedby
a prospective randomized trial comparing the different fractiona-
tionregimens,theanalysisof aconsecutivecohortof patientswith
comparable characteristics and tumors, treated at the same insti-
tution, self-allocated to either of the three regimens can provide
some initial information. The present analysis demonstrates reas-
suring preliminary data that late toxicity at 5years of the 3wCB
schedule is likely to be at least comparable, and acute toxicity
appears to be less.
A 2010 Cochrane Collaboration Intervention Review (James
et al., 2010) addressed the effects of altered fractionation size
on women with early breast cancer who have undergone breast
conservation surgery. Four randomized trials reported on 7095
women with node negative breast cancer, negative margin of sur-
gical resection and tumors measuring less than 3cm in diameter
(89.8%). The results of this analysis demonstrated that compared
tostandardfractionationregimens,accelerated,hypo-fractionated
radiationtherapy(>2Gyperfraction)doesnotadverselyaffectthe
local recurrence risk ratio (RR 0.97, P =0.78), breast appearance
(RR 1.17, P =0.09), or 5-year survival (RR 0.89, P =0.16). Acute
skin toxicity was found to be decreased with hypo-fractionation
compared to standard fractionation (RR 0.21, P =0.007). Many
patients in the randomized trials included in the meta-analysis
received a SB, after completing either hypo-fractionated or stan-
dard radiation. However, none of the studies analyzed compared
a concurrent boost to a sequential one, as compared in this
report.
Finally, current guidelines on the use of hypo-fractionated
treatment tend to exclude patients who receive chemotherapy
from consideration for hypo-fractionated treatment (Smith et al.,
2009). There is only limited prospective data on the effect of
chemotherapy on cumulative normal tissue toxicity after hypo-
fractionated treatment as compared to conventional fractiona-
tion. As compared to Whelan et al. (2010) study where 10.9%
patients received chemotherapy, in this series, approximately a
third of patients received chemotherapy, balanced among the
three treatment groups (P =NS). There was no suggestion of
increasedtoxicityamongthepatientswhoreceivedchemotherapy
and hypo-fractionation.
A limitation of the current report is the relatively short follow
up, limited to 5years. Whelan et al. (2002, 2010) demonstrated
doubling of both skin (6 vs. 3%) and subcutaneous tissue (8 vs.
4%) toxicity with longer follow up. Similarly, among the patients
treated in the EORTC 22881-10882 “boost vs. no boost” trial a
trend toward a dose-dependent development of ﬁbrosis was seen
at 10year follow-up: severe ﬁbrosis occurred in 3.3% after a boost
of 10Gy, 4.4% after 16Gy, and 14.4% after 26Gy, respectively
(Bartelinketal.,2001;Poortmansetal.,2008).Yarnoldetal.(2005)
reported that patients who received a 14-Gy boost on the Royal
MarsdenHospital/GloucesterOncologyCenter(RMH/GOC)trial
had a higher risk of breast induration and telangiectasia than
those who did not receive a boost: however, there was no sta-
tistically signiﬁcant difference between these groups in breast
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appearance,proportionof fairorpoorcosmeticresults,orrisksof
breast shrinkage,breast distortion,breast edema,arm swelling,or
shoulder stiffness (Yarnold et al.,2005).
In this series,all patients were treated using a prone technique.
All three treatments were regimens of 3D conformal radiation to
thewholebreast,witheitheranelectronboostforthe6wSBsched-
uleoranIMRTboostforthetwoacceleratedschedulesofCBtothe
tumor bed.Whether the prone approach permitted better confor-
malityanddosehomogeneitythanstandardsupinesetupremains
to be established.
With a median follow up of 61months, late toxicity was com-
parable among the three groups suggesting that the 3- or 5-week
accelerated regimens utilizing CB, designed on solid BED pre-
dictions, are well-tolerated, with comparable toxicities to those
derived from standard 6week fractionation.
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